In-silico and In-vitro Evaluation of the Anti-diabetic Potential of p‑Propoxybenzoic Acid
Abstract
Background: p-propoxybenzoic acid (p-PBA) is reported as an active chemical constituent of medicinal plants that possess anti-diabetic activity. It is termed a Multiple-Designed Ligand (MDL) having the ability to block more than one enzyme. A molecular docking study justifies the binding ability of p‑PBA with acarbose and NaVO4 which were considered standard compounds having the ability to block target enzymes. α-amylase inhibition assay was used as an in-vitro screening model to evaluate the activity of p-PBA against diabetes on an initial basis.
Methods: For the molecular docking study, a PDB file of p-PBA was prepared and PDB files of α‑amylase (1C8Q), α-glucosidase (5KZW) and PTP1B (5K9W) were procured. p-PBA was docked against the enzymes using the blind docking method. The binding score of p-PBA and standard with enzymes was obtained and compared. The percentage inhibition of an α-amylase enzyme by p-PBA was measured by using a DNS‑modified α-amylase inhibition assay and half-maximal inhibitory concentration (IC50) was calculated.
Results: p-PBA has a significant inhibitory effect against α-amylase, α-glucosidase, and PTP1B with docking scores of 8.43 ± 0.44 kcal/mol, 9.19 ± 0.49 kcal/mol, and 9.40 ± 0.47 kcal/mol respectively. IC50 calculated from the results of α-amylase inhibition assay p-PBA was 56.59 μg/mL.
Conclusion: A combination of in-silico and in-vitro methods assessed p-PBA’s anti-diabetic potential on an initial basis. A molecular docking study involving p-PBA concluded the affinity of p-PBA to α‑amylase, α-glucosidase, and PTP1B was significantly correlated with the affinity of acarbose and NaVO4. In-vitro α‑amylase assay validated the compound’s inhibitory action against the enzyme.
How to cite this article:
Raval K, Tirgar P. In-silico and In-vitro Evaluation of the Anti-diabetic Potential of p‑Propoxybenzoic Acid. Chettinad Health City Med J. 2023;12(1):39-44.
DOI: https://doi.org/10.24321/2278.2044.202307
References
Johnson EC, Ukpe RA, Etim EI, Umoh UF, Eseyin OA, Udoh AE, Mboho T, Anthony PC. In vitro antidiabetic, aphrodisiac and antimicrobial properties of parapropoxybenzoic acid isolated from Acacia auriculiformis A. Cunn Ex. Benth (Fabaceae) stem bark. Trop J Pharm Res. 2021;1;20(3). [Google Scholar]
Lin M, Ke LN, Han P, Qiu L, Chen QX, Lin HT, Wang Q. Inhibitory effects of p-alkylbenzoic acids on the activity of polyphenol oxidase from potato (Solanum tuberosum). Food Chem. 2010;15;119(2):660-3. [Google Scholar]
Bhattacharya S, Chatterjee M. Protective role of Trianthema portulacastrum against diethylnitrosoamine-induced experimental hepatocarcinogenesis. Cancer Lett. 1998;3;129(1):7-13. [PubMed] [Google Scholar]
Raval KY, Tirgar PR. A pre-clinical study to investigate the anti-diabetic potential of p-propoxybenzoic acid as a multi-target inhibitor in streptozotocin-nicotinamide induced type-2 diabetic rats. J Diabetes Metab Disord. 2022. [Google Scholar]
Nawaz HR, Malik A, Ali MS. Trianthenol: an antifungal tetraterpenoid from Trianthema portulacastrum (Aizoaceae). Phytochemistry. 200;1;56(1):99-102. [PubMed] [Google Scholar]
Jeong SY, Nguyen PH, Zhao BT, Ali MY, Choi JS, Min BS, Woo MH. Chemical constituents of Euonymus alatus (Thunb.) Sieb. and their PTP1B and αâ€glucosidase inhibitory activities. Phytother Res. 2015;29(10):1540-8. [PubMed] [Google Scholar]
Raval K, Ganatra T. Basics, types and applications of molecular docking: a review. IP Int J Compr Adv Pharmacol. 2022;15;7(1):12-6. [Google Scholar]
Sethi A, Joshi K, Sasikala K, Alvala M. Molecular docking in modern drug discovery: principles and recent applications. In: Gaitonde V, Karmakar P, Trivedi A, editors. Drug discovery and development-new advances. IntechOpen. 2020;27-48. [Google Scholar]
Saikia S, Bordoloi M. Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets. 2019;20(5):501-21. [PubMed] [Google Scholar]
Pantsar T, Poso A. Binding affinity via docking: fact and fiction. Molecules. 2018;23(8):1899. [PubMed] [Google Scholar]
Kairys V, Baranauskiene L, Kazlauskiene M, Matulis D, Kazlauskas E. Binding affinity in drug design: experimental and computational techniques. Expert Opin Drug Discov. 2019;3;14(8):755-68. [PubMed] [Google Scholar]
Sulimov VB, Kutov DC, Sulimov AV. Advances in docking. Curr Med Chem. 2019;1;26(42):7555-80. [PubMed] [Google Scholar]
Bolcato G, Cuzzolin A, Bissaro M, Moro S, Sturlese M. Can we still trust docking results? An extension of the applicability of DockBench on PDBbind database. Int J Mol Sci. 2019;20(14):3558.[PubMed] [Google Scholar]
Geethalakshmi R, Sarada DV. α-Amylase inhibitory activity of Trianthema decandra L. Int J Biotech Biochem. 2010;1;6(3):369-76. [Google Scholar]
Devaki K, Beulah U, Akila G, Sunitha M, Narmadha R, Gopalakrishnan VK. Effect of aqueous leaf extract of B. tomentosa on GTT of normal and diabetic rats. Pharmacologyonline. 2011;3:195-202. [Google Scholar]
Song YH, Uddin Z, Jin YM, Li Z, Curtis-Long MJ, Kim KD, Cho JK, Park KH. Inhibition of protein tyrosine phosphatase (PTP1B) and α-glucosidase by geranylated flavonoids from Paulownia tomentosa. J Enzyme Inhib Med Chem. 2017;32(1):1195-202. [PubMed] [Google Scholar]
Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct. 2003;32:335-73. [PubMed] [Google Scholar]
Cross JB, Thompson DC, Rai BK, Baber JC, Fan KY, Hu Y, Humblet C. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. J Chem Inf Model. 2009;49(6):1455-74. [PubMed] [Google Scholar]
Kato-Schwartz CG, Corrêa RC, de Souza Lima D, de Sá-Nakanishi AB, de Almeida Gonçalves G, Seixas FA, Haminiuk CW, Barros L, Ferreira IC, Bracht A, Peralta RM. Potential anti-diabetic properties of Merlot grape pomace extract: an in vitro, in silico and in vivo study of α-amylase and α-glucosidase inhibition. Food Res Int. 2020;137:109462. [PubMed] [Google Scholar]
Singh R, Chandel S, Dey D, Ghosh A, Roy S, Ravichandiran V, Ghosh D. Epigenetic modification and therapeutic targets of diabetes mellitus. Biosci Rep. 2020;30;40(9):BSR20202160. [PubMed] [Google Scholar]
